| Literature DB >> 31679864 |
Mu-Lin Chiu1, Shu-Ting Luo1, Ya-Yen Chen1, Wan Yu Chung1, Veasna Duong2, Philippe Dussart2, Yoke-Fun Chan3, David Perera4, Mong How Ooi5, Nguyen Thi Thanh Thao6, Huu Khanh Truong7, Min-Shi Lee8.
Abstract
Enteroviruses (EV), the major pathogens of hand, foot, and mouth disease (HFMD) and herpangina, affect millions of children each year. Most human enteroviruses cause self-limited infections except polioviruses, enterovirus A71 (EV-A71), enterovirus D68 (EV-D68), and several echoviruses (Echo) and coxsackieviruses (CV). Especially, EV-A71 has repeatedly caused large-scale outbreaks in the Asia-Pacific region since 1997. Some Asian countries have experienced cyclical outbreaks of severe EV-A71 infections and initiated development of EV-A71 vaccines. Five EV-A71 vaccine candidates have been clinically evaluated and three of them were approved for marketing in China. However, none of the China-approved products seek marketing approval in other countries. This situation supports a role for collaboration among Asian countries to facilitate clinical trials and licensure of EV-A71 vaccines. Additionally, enterovirus D68 outbreaks have been reported in the US and Taiwan currently and caused severe complications and deaths. Hence, an Asia-Pacific Network for Enterovirus Surveillance (APNES) has been established to estimate disease burden, understand virus evolution, and facilitate vaccine development through harmonizing laboratory diagnosis and data collection. Founded in 2017, the APNES is comprised of internationally recognized experts in the field of enterovirus in Asian countries working to raise awareness of this potentially fatal and debilitating disease. This article demonstrated the summaries of the first expert meeting, 2017 International Workshop on Enterovirus Surveillance and Vaccine Development, held by APNES in Taipei, Taiwan, March 2017.Entities:
Keywords: Asia-Pacific region; Enterovirus; Vaccine
Year: 2019 PMID: 31679864 DOI: 10.1016/j.vaccine.2019.09.111
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641